Marc de Garidel


Marc de Garidel
  • More than 35 years of global leadership experience and value creation in the life science industry
  • Previously Chief Executive Officer of Corvidia Therapeutics, a private Boston-based cardiorenal-focused clinical-stage company that was acquired by Novo Nordisk in July 2020 for $2.1 Billion
  • Chairman of Ipsen SA since 2010; Ipsen CEO from 2010 to 2016, where he led a significant transformation of Ipsen, effecting a three-fold increase in market capitalization, launching the blockbuster oncology drug Somatuline Depot (lanreotide) in the U.S., and completing an ex-U.S. commercialization deal with Exelixis on CABOMETYX (cabozantinib)
  • 15 years at Amgen, initially joining as the company’s Chief Financial Officer in Europe and ultimately leading the South Region of Amgen International, responsible for operations across most of Europe and Latin America
  • Master’s in Civil Engineering from ETP in Paris, Master’s in Management from the Thunderbird School of Global Management, and an Executive MBA from Harvard Business School